ORYZON Announces End of Patient Recruitment for its Phase IIa trials in aggression with vafidemstat: REIMAGINE and REIMAGINE-AD

by Oryzon Genomics

5 years ago
ORYZON, trials, patient, REIMAGINE, REIMAGINE-AD, psychiatric disorders, Alzheimer

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announce...

ORYZON Receives $1.5 million grant from Alzheimer’s Drug Discovery Foundation (ADDF)

by Oryzon Genomics

5 years ago
help fund, ADDF, Alzheimer’s Drug, Oryzon

Proceeds to help fund ETHERAL-US Phase IIa examing vafidemstat in Alzheimer’s disease. ADDF stake in the company represents 0.94% of the common stock.

Oryzon presente en conferencias de reconocido prestigio internacional

by Oryzon Genomics

5 years ago
Oryzon, conferencias, prestigio

Oryzon Genomics, S.A., compañía biofarmacéutica de fase clínica centrada en la epigenética para el desarrollo de terapias en enfermedades con importantes necesidades médicas no resueltas, ha anu...

Oryzon presenta hoy sus primeros resultados de eficacia en pacientes tratados con Vafidemstat en el 27º Congreso Europeo de Psiquiatría en Varsovia

by Oryzon Genomics

5 years ago
Oryzon, Vafidemstat, Congreso, epigenética, TLP, ASD, TDAH, Vall d'Hebron

ORYZON Announces Publication of a relevant paper for the therapeutic development of Iadademstat (ORY-1001) in Small Cell Lung Cancer (SCLC)

by Oryzon Genomics

5 years ago
ORYZON, Iadademstat, publication, antitumor drug, Lung cancer

Complete and durable tumor regression occurred with Iadademstat–induced NOTCH activation in a chemoresistant PDX model. Further supports LSD1 inhibitors as a possible new and targeted therapy for SC...

Oryzon , la compañía española que desarrolla terapias experimentales epigenéticas innovadoras, anuncia sus resultados y avances en el primer semestre de 2018

by Oryzon Genomics

6 years ago
Oryzon, epigenética

ORYZON announces new grant from Alzheimer’s Drug Discovery Foundation (ADDF) to develop a companion marker for its ORY-2001 epigenetic drug

by Oryzon Genomics

7 years ago
Oryzon, clinical trial, Alzheimer’s Drug Discovery Foundation, ORY - 2001, epigenetics

Oryzon is finishing an on going double - blind, placebo - controlled Phase 1 clinical trial in healthy volunteer s of its proprietary oral LSD1 - MAOB dual selective inhibitor ORY - 2001. The company ...

ORYZON to Present Clinical Data on LSD1 Inhibitor ORY-1001 at ASH 2016

by Oryzon Genomics

8 years ago
ORY-1001, Roche, Oryzon, leukemia

ORY - 1001 (RG6016), Oryzon’s first clinical asset, is a highly potent and selective Lysine Specific Demethylase - 1 (LSD1) inhibitor for the treatment of leukemia and other malignancies, currently ...

Oryzon raises $ 19 Million in Private Placement to Advance Therapeutic Programs

by Oryzon Genomics

9 years ago
Oryzon, Najeti, Active Motif, Costex, Corporación Sant Bernat SCR, Grupo Ferrer Internacional, Fondo Capital MAB, Institut Català de Finances (ICF)

Carlos Buesa, Oryzon’s Co-Founder, President and Chief Executive Officer commented, " The success of this capital raise is affirmation that investors , some of them specialized in the epigenetics fi...

Roche and Oryzon announce collaboration to develop epigenetics-based medicines

by Oryzon Genomics

10 years ago
Oryzon, Roche, haematology, cancer, genomics, epigenetics

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Oryzon Genomics SA today announced they have entered into a worldwide collaboration to research, develop and commercialize inhibitors of Lysine Specific Demethyl...